The latest cancer drugs news
Browsing: Cancer Drug News
FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations
On September 19, 2024, the Food and Drug Administration approved amivantamab-vmjw with carboplatin and pemetrexed…
FDA approves selpercatinib for RET fusion-positive medullary thyroid cancer
On September 27, 2024, the Food and Drug Administration granted traditional approval to selpercatinib for…
FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
On September 20, 2024, the Food and Drug Administration approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC)…
Precision drug olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancer
The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying…
FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer
On August 19, 2024, the Food and Drug Administration approved lazertinib (Lazcluze, Janssen Biotech, Inc.)…
FDA approves new therapy for glioma patients for first time in decades
Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with…
FDA approves blood test as a primary screening option for colorectal cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced that the U.S.…
FDA approves vorasidenib
A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma,…
Drug developed for pancreatic cancer shows promise against most aggressive form of medulloblastoma
A drug that was developed to treat pancreatic cancer has now been shown to increase…
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple myeloma
On July 30, 2024, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj in combination with…